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Simple Summary: TARGET (tumour characterisation to guide experimental targeted therapy)
matches patients entering early phase cancer clinical trials to the best treatment for them based
on their genetics. Selecting only fit patients for these trials means less patients need to be recruited.
Fit patients have a life expectancy of >three months. Performance status (PS) is used to measure life
expectancy and is decided by doctors asking questions about patient’s activity levels. We created a
Wellness Score using proteins in 55 patient’s blood samples. This score groups patients into those
who were likely to die and those who were likely to be alive within six months of their blood sample.
This score was more accurately able to predict a patient’s survival at six months than PS. We then
reached the same conclusion in a further 77 patients. We hope this score can now be tested in an even
larger group of patients.
Abstract: TARGET (tumour characterisation to guide experimental targeted therapy) is a cancer
precision medicine programme focused on molecular characterisation of patients entering early phase
clinical trials. Performance status (PS) measures a patient’s ability to perform a variety of activities.
However, the quality of present algorithms to assess PS is limited and based on qualitative clinician
assessment. Plasma samples from patients enrolled into TARGET were analysed using the mass
spectrometry (MS) technique: sequential window acquisition of all theoretical fragment ion spectra
(SWATH)-MS. SWATH-MS was used on a discovery cohort of 55 patients to differentiate patients into
either a good or poor prognosis by creation of a Wellness Score (WS) that showed stronger prediction
of overall survival (p = 0.000551) compared to PS (p = 0.001). WS was then tested against a validation
cohort of 77 patients showing significant (p = 0.000451) prediction of overall survival. WS in both sets
had receiver operating characteristic curve area under the curve (AUC) values of 0.76 (p = 0.002) and
0.67 (p = 0.011): AUC of PS was 0.70 (p = 0.117) and 0.55 (p = 0.548). These signatures can now be
evaluated further in larger patient populations to assess their utility in a clinical setting.
Keywords: biomarkers; cancer; swath; proteomics
1. Introduction
The development of personalised healthcare and targeted therapies requires the
parallel development of companion biomarkers [1]. Such markers have great potential
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to be used in the personalised assessment of disease through prognostic, predictive or
diagnostic means. Characterisation of patient selection biomarkers better informs the
clinical decision both for clinical trials as well as for improving standard of care in medicine
generally. Whilst genetic biomarkers and mRNA transcripts are typically analysed for
patient selection, a majority of patients have no clear genomic driver of their disease. In
contrast, proteins are the main target for many drugs and provide a higher amount of
functional information and insight into cellular and organismal state compared to nucleic
acid markers [2,3]. Thus, detailed proteomic analyses will provide insights for future
patient selection to early phase clinical trials. The prognostic relevance of proteins is also
important in helping to select patients to early phase clinical trials. The precedent for
proteins as a prognostic biomarker is demonstrated, for example, by haemoglobin (Hb)
and lactate dehydrogenase (LDH) that have already been used in determining health status
and prognosis in patients prior to enrolment in early phase cancer clinical trials [4,5].
Performance status (PS) was developed 70 years ago to assess patient’s ability to
perform day-to-day activities. The Eastern Cooperative Oncology Group (ECOG)/World
Health Organisation (WHO) scale developed in 1982 is now the most widely used scale,
scoring patients on a scale of 0 to 5. Scores are defined as in Table S1.
The subjective nature of the PS scale has led to recognition that there is a requirement
for improvement in the early phase cancer clinical trial setting. Early phase cancer clinical
trials are designed with the aim of identifying the side effects and correct dosage levels
of a given investigational medicinal product (IMP) alongside initial efficacy evaluation.
Patients considered for early phase cancer trials typically have advanced stage disease and
have usually received prior therapies. Being able to predict which patients are fit enough
for enrolment into a cancer clinical trial is important from a patient safety perspective and
ensuring robust evaluation of the IMP. Early phase clinical trial inclusion criteria normally
requires an acceptable PS score of either 0 or 1 and a life expectancy of >3 months [6].
Side effects are more life threatening to the patient volunteering for the trial with poorer
PS [6]. Developing a more objective and quantitative tool than PS which is more suited to
assessing patient status may enhance patient selection to early phase studies. Using new
‘omic’ approaches offers opportunity for inclusion of quantified biomolecules. Proteomic
measures on peripheral blood have been studied as a means of assessing patient survival
and health status [7–9]. In addition to using PS, routine measurement of albumin, LDH
and Hb have been employed to assess patient wellness with well-studied correlations
between circulating levels and patient survival [5,10–12]. Prognostic scoring systems have
been previously developed using different methodologies and techniques. Examples of
these scoring methods include the real-world prognostic score (ROPRO) [10] which was
calculated using routine clinical variables from over 120,000 patients to provide impressive
prognostic utility, the Royal Marsden prognostic score [11], the inflammation-based Glas-
gow prognostic score (GPS) [12] which uses albumin and C-reactive protein levels and the
international Metastatic Renal-Cell Carcinoma Database Consortium prognostic model [13]
which uses haemoglobin, calcium, neutrophil and platelet levels along with the Karnofsky
performance status [14].
A multidisciplinary approach in biomarker discovery and validation provides a higher
probability of identifying more accurate and sensitive tests [15]. Mass spectrometry (MS)
based plasma proteomics can be employed to develop a wellness assessment [16]. The large
number of proteins assessed using MS offers deep insight into the individual phenotype
and has a level of specificity that is required in bioassays [17,18], especially when combined
with an artificial intelligence based approach to data interrogation [19,20].
The wide heterogeneity of patient cancer phenotypes is a confounding factor in
developing sensitive and specific algorithms for clinically relevant information to be
derived. Plasma protein biomarkers can allow for the separation of patients into groups
depending on their prognostic scoring. Proteomics has been shown to be a useful tool in
early diagnosis [21,22], prediction of wellness [23], treatment allocation [24,25], disease
progression and aetiology [26,27] as well as predicting drug resistance [24].
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Sequential window acquisition of all theoretical fragment ion mass spectra (SWATH-
MS) is a biomarker discovery tool that can be used to identify many proteins in a consis-
tently reproducible way [28]. SWATH-MS uses the reproducibility and relatively swift
sample preparation and run time plus standardised informatics capabilities to generate
digitised proteomic maps. SWATH-MS has been used to identify proteomics signatures in
a wide range of diseases and conditions with recent cancer based studies finding signatures
of interest in breast and colorectal cancer [29,30], endometrial cancer [31], ovarian [32] lung
cancer [33] and other health conditions such as weight loss [34].
SWATH-MS techniques generate fragment spectra from all MS measurable peptides
that are within a sample allowing for the analysis of a wider range of typically low abun-
dance biomarkers [35–38]. We have taken the SWATH-MS platform and applied it to
samples collected as part of the TARGET (tumour characterisation to guide experimental
targeted therapy) study. The TARGET trial is an initiative to optimise the pathway for
molecular characterisation of all patients being considered for early phase cancer trials in
order to inform clinical decisions as to their optimal treatment [39]. Patients are matched
to relevant therapies in the early phase clinical trials on the basis of molecular screening
and/or disease type. Nonetheless wellness to engage on a clinical trial is still relatively
subjectively assessed with scoring algorithms lacking sensitivity [40,41]. Here we have
taken 10 patient variables including standard prognostic parameters and assessed the
plasma proteomic profile. With these data we sought to develop an improved prognostic
algorithm. The aim of this study was therefore to identify potential proteomic biomarkers
that have prognostic value in determining the wellness of patients enrolling into phase 0/I
trials in a discovery and validation set in order to assess the capability of translating these
markers into clinical utility.
2. Materials and Methods
2.1. Clinical Sample Collection
The TARGET trial was conducted in line with the principles of the Declaration of
Helsinki and Good Clinical Practice. The trial was approved by the North-West (Preston)
National Research Ethics Service, in February 2015 (15/NW/0078) and is registered in
the NIHR Central Portfolio Management System (CPMS ID 39172). All patients were
recruited by the Experimental Cancer Medicine Team at The Christie NHS Foundation
Trust, Manchester, UK. All patients provided fully informed written consent for provision
of tumour and blood samples and clinical data.
The study design and eligibility criteria have been described previously [36]. Briefly,
the TARGET trial was split into two parts. In part one, the aim was to assess the ctDNA and
tumour sequencing workflow and its capabilities in stratifying patients. In part two, the
aim was to expand the study in order to stratify patients into clinical trials and therapies
in real time. For this investigation, 73 patients were used as the discovery cohort and 79
patients used as the validation cohort.
2.2. Proteomic Sample Collection and Preparation
Double-spun plasma samples were collected using 10 mL EDTA tubes. Blood was
spun within 96 h of collection prior to storage at −80 ◦C. Plasma samples taken at the
patient’s baseline visit for enrolment into the TARGET trial were used for this study. For
the discovery phase of the study, 73 patient samples were used, however 18 samples did
not pass quality checks (e.g., due to haemolysis or presence of cell lysis products) and these
patients were not included in the analysis. For the validation phase of the study, 2/79
samples did not pass quality control filters. Our workflow only assesses tryptic peptides
in order to avoid endogenous protease activity affecting our quantification. Furthermore,
we have assessed leaving plasma samples on a lab bench at room temperature for varying
levels of time and have observed no effect on the relative abundance levels of the proteome.
Plasma samples were depleted of the top 12 most abundant proteins using the com-
mercially available Top-12 kits (Pierce, Thermo, Loughborough, UK) according to the
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manufacturer’s methods. The resultant solution was assayed for the protein amount using
a Bradford reagent (Bio-Rad, Watford, UK). Solution containing 40 µg worth of protein was
taken and processed further. Samples were reduced using 60 mM TCEP at 60 ◦C for 60 min
followed by alkylation using 10 mM iodoacetamide in the dark for 30 min. Digestion was
performed using trypsin (Promega, Southampton, UK) overnight at 37 ◦C in a 10:1 ratio
of protein to enzyme. Digested peptides were cleaned using a SepPak (Waters, Wilmslow,
UK) 96 well plate SPE system.
2.3. SWATH-MS Analysis
Mass spectrometry was performed using a 6600 TripleTOF (Sciex, Warrington, UK).
The LC method was a 120-min gradient between a buffer A of 98% Water, 2% (v/v) Ace-
tonitrile and 0.1% (w/v) Formic Acid and a buffer B of 80% Acetonitrile, 20% Water, 0.1%
Formic Acid. Samples were injected in duplicate. In the discovery set, a Dionex Ultimate
3000 HPLC was connected in-line (Dionex, Thermo, Loughborough, UK) and the peptide
samples were loaded onto a trap column, 5 µm C18 PepMap 100 (Thermo, Loughborough,
UK), for 10 min at 5 µL/min before loading onto an Acclaim C18 PepMap 100 analytical
column at 300 nL/min (Thermo, Loughborough, UK). In the validation set, an Eksigent
system comprising of a nanoLC 400 autosampler along with a 425 pump module were
used with a YMC-Triart C18 trap column and a YMC-Triart C18 analytical column. Spectra
were acquired in a SWATH mode method utilising the 100 variable window method with
MS2 windows ranging from 399.5 to 1249.5 m/z with optimised collision energy equations.
MS1 mass range was between 100–1500 m/z with an accumulation time of 0.05 s and a cycle
time of 2.6 s.
Spectral data files were converted using wiffconverter (Sciex, Warrington, UK) to
mzML format prior to search using openSWATH (Version 2.0.0) against a the publically
available twin plasma library (version published 5 January 2015) [42]. openSWATH results
files were processed using pyProphet before being aligned using the feature alignment
script from MSproteomicstools with a target FDR of 0.01 at the PSM level. Data are available
via ProteomeXchange with identifier: PXD023553.
2.4. Statistical Analysis
Data analysis was performed using R (Version 3.4.1) and the IBM Statistical Product
and Service Solutions (SPSS) (Version 25). For SWATH-MS data in both the discovery and
validation cohorts, the Bioconductor (Version 3.5) packages MSstats and SWATH2Stats
were used for downstream processing. Coefficients of variation were calculated between
technical replicates with any samples showing a median CV of 20% or higher being re-run,
this resulted in 15 samples being re-injected. The median CVs of all samples ranged from
5.6% to 18.9% with a median of 7.9%. An example correlation between two technical
replicates is shown in Supplemental Figure S1. Data was filtered by mscore using the
filter_mscore_fdr function in the SWATH2stats package with an overall protein FDR target
of 0.02 and an upper overall peptide FDR limit of 0.05. Data was converted from a fea-
ture alignment output to MSstats input using SWATH2stats’s convert4MSstats function.
MSstats was used for normalisation and summarisation of protein intensities using the
dataprocess function utilising the default arguments. Missing values were imputed using
the Muiltivariate Imputation by Chained Equations (MICE) package (Version 2.3) using
only proteins seen in 70% of the samples. The proteins verses samples matrix was im-
puted using the default arguments of the mice function with the predictive mean matching
method and the random seed set to 500. Significance between protein abundances were
calculated using the Limma package using the empirical Bayes statistics for differential
expression method. Significance was set as p < 0.05, 95% confidence intervals were deter-
mined where necessary as advised in text. RandomForest was employed by separating the
discovery data into training and testing sets at a 70% split. A total of 1000 models were
created and the protein importances were ranked across all models. Accuracy was used
as the parameter to optimise. For categorical variables, a value of 0 was allocated to the
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favourable category and a 1 for not favourable. Univariate and multivariate analysis was
evaluated using Cox regression. Overall survival was measured from the date of consent
to TARGET to date of death of any cause. To determine the impact of all the collected
variables in the demographic characteristics on the patient’s allocation to the wellness
score (WS) groups, a two-sided Fisher’s exact tests were used in groups with fewer than
five patients and a Pearson’s Chi squared tests were utilised when there were more than
five patients in a group. Overall survival was determined using Kaplan–Meier curves.
ROC curves and AUC were used to determine the prognostic abilities of the scores created.
Evaluation of the prognostic biomarkers was performed taking into account the REporting
recommendations for tumour MARKer prognostic studies (REMARK) guidelines [38].
2.5. Clinical Prognostic Parameters
Full clinical patient demographics and clinical characteristics can be found in Table S3
along with a boxplot showing the distribution of patients with each PS (Figure S2). Lines
of treatment were considered new when they were given after documented clinical or
radiological disease progression. Any treatment given to cure disease, for example surgery
or to slow progression were counted as treatment. If treatment was only given for symptom
control (e.g., palliative radiotherapy), this was not counted. Number of treatment lines
was used to determine how heavily pre-treated patients had been. Sites of disease were
identified using the patient’s most recent computed tomography (CT) scan taken before
they enrolled into TARGET. Sites of disease were counted if there was disease present at
the time of the scan. If a site of disease had been removed via surgery and had not recurred,
it was not counted. An ‘above diaphragm’ and ‘below diaphragm’ was used for counting
lymph nodes, the maximum number of lymph nodes counted as a site per person was two.
Patients with one site of disease were allocated a 0 and patients with greater than one site
of disease were allocated a two.
Data for circulating blood levels of albumin, LDH and Hb were collected on all patients
in both cohorts upon entry into the TARGET trial because they have been used previously
as prognostic biomarkers alongside PS [10]. Poor prognostic cut-offs were defined as low
serum albumin less than 35 g/L (Figure S3); high LDH > 500 IU/L (Figure S4) and low Hb
(anaemia), <115 g/L (Figure S5).
Patient overall survival was calculated from the date of consent to the TARGET trial.
Patient survival status was accurate as of 10 May 2019.
3. Results
3.1. Determination of a Discriminatory Panel
Using SWATH-MS we derived a proteomic map of all the plasma samples in the dis-
covery set. In total 995 proteins were identified (>1 proteotypic peptide, Tables S5 and S6).
The results had a mean assay FDR of 0.14; 550 proteins were seen in >70% of all samples. A
total of 77 proteins were significantly (p ≤ 0.05) different between samples from patients
who died within 6 months of plasma sampling and those who died beyond 6 months.
Machine learning techniques were utilised to identify candidate proteins to assess fur-
ther in downstream statistical analysis. SVC, K Nearest neighbour and RandomForest
analyses were employed on all the proteins. RandomForest results created the panel with
the strongest discrimination. A shortlist of 15 proteins were isolated as providing the
best differentiation.
This list of proteins was then filtered down further by Cox regression analysis which
determined the significance of each protein on overall survival (OS) (Table 1). For a clin-
ically viable assay the number of proteins for measurement needs to be limited. Three
proteins of interest had a significant correlation with overall survival. A PCA (Figure 1)
showed separation between the different experimental groups using this shortlist of three
proteins. Within the PCA the different experimental groups separated on the first principal
component with an explained variation of 51.6%. One protein showed a positive correla-
tion, and two proteins showed a negative correlation (positive correlation was increased
Cancers 2021, 13, 2443 6 of 18
amount of protein correlated with an increased risk of death over time from consent to
the last time point the patient was seen alive). The protein with a positive correlation
was Leucine-rich alpha-2-glycoprotein. The two proteins with a negative correlation were
Apolipoprotein C-III and Plasma serine protease inhibitor.
Table 1. Proteins showing a significant (p < 0.05) Cox regression against overall survival along with
hazard ratios and confidence intervals (CI).
Protein Name
(Correlation) p Value Hazard Ratio Lower 95% CI Upper 95% CI
A2GL (+) 0.001 2.328 1.394 3.887
APOC3 (−) 0.023 0.7 0.514 0.952
IPSP (−) 0.013 0.437 0.227 0.84
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In the validation set, chi-squared test showed a significant correlation between Wellness
Score and baseline LDH (p = 6.3 × 10−5).
The variables found to be significant at univariate analysis were put in a multivariate
analysis for both data sets. The p values for Wellness Score, sites of disease and PS were
p = 4.0 × 10−5, p = 0.021 and p = 0.001 in the discovery cohort and p = 6.5 × 10−5, p = 0.004
and p = 0.044 in the validation cohort at multivariate analysis. Although PS was not found
to be significant in the validation set, as it was found to be significant at multivariate
analysis, it was taken forward for score creation. Two more scores were generated for
comparison, the first being an Enhanced Proteomics PS Score (PEPS). This was calculated
by adding together the Wellness Score (0 for low and 1 for high) and PS (0 for PS 0 and 1
for PS 1–2) to create a score out of 2. The third score generated was a Phase I Proteomics
score (PPM) by adding in variables that were significantly related to overall survival in the
multivariate analysis. With a single disease site being represented as a 0 and multiple sites
represented as a 1. PS was represented as before in the PEPS. The addition of the disease
site value to the PEPS gave a PPM score out of 3. Score allocation summaries can be found
in Table S3.
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Kaplan–Meier analysis was used to estimate the survival function when stratifying
patients using each of the different scores generated. The Wellness Score approach (Figure 4)
showed a significant difference in overall survival between the those with a good outcome
Wellness Score and those with a poor outcome score with regards to overall survival in both
the discovery cohort and validation cohort (p = 5.5 × 10−4 and 4.5 × 10−4 respectively). The
number of patients separating into each Wellness Score group and survival status showed
a similar pattern between discovery and validation (Figure S6). In the discovery cohort
positive predictive value (PPV) of the Wellness Score of overall survival at six months was
96% and negative predictive value (NPC) of 60% (Table 2). The validation set had a PPV of
74% and a NPV of 60%. The Wellness Score was able to accurately predict the outcomes at
six months of 75% of patients in the discovery set and 66% in the validation. PS (although
not a tool created to predict patients’ outcomes at six months) had a PPV of 47% in the
discovery cohort, with an NPV of 60%. In the validation cohort, PS PPV was 54% and NPV
59%. In respect of early phase clinical trials activity it would appear a Wellness Score could
be useful for enrolment in such clinical trials by adding a further means of stratification,
as the PPV of WS in greater than PS at predicting if a patient will be alive in six months.
As using PS score alone had a lower predictive capability, the use of a combined score
comprising of PS, the number of disease sites and Wellness score was investigated in a
combined Phase I proteomics score PPM score.
Table 2. Positive and negative predictive values of Wellness Score and PS in the discovery and
validation cohorts at six months.
Predictive Values Discovery Validation
WS PPV 96% 74%
PS PPV 47% 54%
WS NPV 60% 59%
PS NPV 60% 59%
As seen in Table 3 we now have shown a significant difference between the two
stratified patient groups regarding overall survival in the discovery cohort as well as
the validation cohort (p = 4.4 × 10−6 and 7.5 × 10−5 respectively), using proteomics to
derive markers.
PS (Figure 5) was not able significantly stratify patients in the validation cohort
(p = 0.084) but was able to in the discovery group (p = 0.001). PPM (Figure 6) also showed
a significant difference in stratifying patients into three groups, within the discovery
(p = 4.4 × 10−6) and validation cohorts (p = 7.4 × 10−7). PEPS (Figure 7) showed a signifi-
cant difference between the two stratified patient groups regarding overall survival in the
discovery cohort and in the validation cohort (p = 5.3 × 10−5 and 7.5 × 10−5 respectively).
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The difference scores were assessed using receiver operatic characteristics curves
(Figure 8). The false positive rate, or specificity, was plotted against the true positive rate,
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or sensitivity. Wellness Score had an AUC of 0.755 with a p value of 0.043 in the discovery
cohort and an AUC of 0.713 with a p value of 0.009 in the validation cohort. The PS score
had an AUC of 0.697 with a p value of 0.117 in the discovery cohort and an AUC of 0.549
with a p value of 0.548. PPM score had an AUC of 0.832 with a p value of 0.008 in the
discovery cohort and an AUC of 0.745 with a p value of 0.003 in the validation cohort. PEPS
score had an AUC of 0.810 with a p value of 0.014 in the discovery cohort and an AUC of
0.733 with a p value of 0.004 in the validation cohort. The different scores, as predictors,
were then tested at different time points prior to death. ROC analysis showed an AUC of
0.756 and a p value of 0.002 at six months from consent (Figure 9) and an AUC of 0.733 and
a p value of 0.003 at nine months in the discovery set. Other time periods were tested but
showed a less significant model than nine months (Table S4). A direct comparison with
published prognostic scoring systems was not immediately possible given the patient data
obtained from patients entering the TARGET trial. A comparison with GPS was possible
using the proteomic data obtained through SWATH-MS and the levels of albumin recorded
upon patient consent. To make the GPS modified score, SWATH-MS determined protein
abundance levels of C-reactive protein (CRP) were normalised. Patient samples with a
CRP normalised abundance greater than 0 were given a CRP score of 1 and all those with a
normalised abundance below 0 got a CRP score of 0. Albumin was divided into <35 g/L = 1
and >35 g/L = 0. These were then added together to make a GPS modified score. No
patient sample in the discovery set had both a high CRP score and a low albumin score so
no patients had a GPS modified score of 2 and only one patient sample in the discovery set
had an albumin of <35 g/L. Kaplan–Meier analysis of the modified GPS (Figure S7) showed
no significant difference in overall survival between scores in the discovery set but found
a significant difference in the validation set (p = 0.774 and 2.36 × 10−7 respectively). A
ROC curve of the modified GPS was plotted in addition to the curves in Figure 8, shown in
Figure S8. The two patient cohorts showed a disproportionate amount of colorectal cancer
patients compared to other cancer types, considering that leucine-rich alpha-2-glycoprotein
was a constituent part of the protein panel the Kaplan–Meier analysis on the Wellness Score
was repeated but with the colorectal cancer patients excluded from the analysis (Figure S9).
The analysis still showed a significant difference in overall survival between those with a
good outcome Wellness Score and a poor outcome Wellness Score in both the discovery
and validation cohorts (p = 0.005 and 0.0144 respectively).
Table 3. Median overall survival (OS) and significance of Wellness Score, Enhanced Proteomics PS score (PEPS), Phase I
proteomics score (PPM), and Performance Status (PS) in the discovery and validation cohorts.
Scoring System Score Discovery n Discovery Median OS (Days) Validation n Validation Median OS (Days)
Wellness Score 0 34 377 35 407
1 21 148 42 167
p value 5.5 × 10−4 4.5 × 10−4
PPM 0 6 1052 3 593
1 16 572 16 407
2 18 257 36 283
3 15 112 22 153
p value 4.4 × 10−6 7.4 × 10−7
PEPS 0 16 467 14 486
1 20 377 36 298
2 19 130 27 153
p value 5.3 × 10−5 7.5 × 10−5
PS 0 18 628 29 298
1 (+2) 37 296 49 196
p value 0.001 0.084
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4. Discussion
Cancer patients enrolling into early phase clinical trials are a heterogenous group
having a diverse range of cancer types and treatment histories. To ensure successful trials
and to limit the unnecessary exposure of patients to treatments which they stand little
chance of benefiting from as their disease is progressing too fast, a robust and reliable
means of determining patient prognosis is needed. PS is one of the measures routinely
used for determining whether patients are eligible for enrolment into early phase clinical
trials. Many trials have a restriction of an expected life expectancy of 3–6 months required
for patients to join the trial [39]. The subjective nature of PS allows for bias to be introduced
from either the patient or the person assessing them. A routine blood protein test could
provide a more objective means to determine the wellness of patients, their likely prognosis
and their suitability for trials.
The proteins identified in our study have been seen previously with biological links to
cancer. Leucine-rich alpha-2-glycoprotein has been used recently as a potential diagnostic
marker in colorectal cancer [40] and it has shown potential use as a prognostic marker
and treatment target in oesophageal squamous cell carcinoma [41]. A high amount of
leucine-rich alpha-2-glycoprotein has been shown to promote angiogenesis which could
indicate an increased amount of cancer invasion and metastasis [43]. Apolipoprotein
C-III and other apolipoproteins have been identified as being significantly abundant in
liver and lung cancer and the protein family has been identified as a potential target for
diagnostic and prognostic markers [42]. A low level of apolipoprotein C-III would indicate
a lower capability of the body to inhibit fat degradation and low levels of apolipoprotein
C-III are observed in gastric cancer where blood lipid levels are correlated with disease
progression [44]. Plasma serine protease inhibitor has been shown to have links with
lung and ovarian cancer with the potential use as a prognostic marker [43,44]. A plasma
serine protease inhibitor decrease is association with cancer metastasis, migration and
invasion [45,46]. While the proteins in the panel in the Wellness Score have been linked
with individual cancer types before in prognostic capacity, the use of these proteins in
defining the wellness of patients across a wide range of cancers as experienced in early
phase cancer clinical trials has not been identified previously.
In our initial discovery phase of the study, we were successful in identifying protein
biomarkers that may have the potential for later development into a routine assay that
facilitates appropriate enrolment into clinical trials whilst being sufficiently tractable to
enable its usage to characterise patient wellness prior to starting a clinical trial using the
Wellness Score. The significant results of this score were replicated in the validation cohort.
This has demonstrated the capabilities of using proteomics to discover novel prognostic
biomarkers for the stratification of patients into those whose disease is advancing so
rapidly that there is only a short window for new investigational medicinal products to
demonstrate efficacy. This is particularly pertinent for those investigational medicinal
products which may have delayed responses—such as the immune-modulating class of
drugs. The successful discovery of a set of protein biomarkers highlights the ability of
discovery techniques such as SWATH-MS to find previously unknown biomarkers. Data-
independent mass spectrometry analysis has gone through rapid development since its
inception into proteomics. Recent work by the Markus Ralser group [47] has shown that it
is possible to create ultra-high throughput workflows with sample to sample run-times of
5 min. SWATH-MS has been found to be robust in terms of reproducibility and quantitative
variability between different instruments and laboratory sites [48]. While SWATH-MS
presents an attractive option for use in a clinical setting in the future, presently more
appropriate to generate assays utilising established methods of widespread routine clinical
analysis. Single-reaction monitoring (SRM) based mass spectrometry along with antibody
based quantitative methodologies such as ELISAs have long been established as routine
tools in clinical laboratories [32]. The framework and experimental paradigm presented in
this study, using SWATH-MS based proteomics along with statistical analysis to generate
scoring systems, can be utilised further in different diseases and tissue types.
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ROC curves of the different scores between the two cohorts showed that all the scores
(except for PS in the discovery cohort) were accurate predictors in both the discovery
cohort and in the validation cohort. The Wellness Score alone was a significant means
to estimate overall survival in both cohorts. A comparison with the Glasgow prognostic
score showed that Wellness Score provided stronger results indicating it could have the
potential to be developed into a test that may be applicable to clinical settings in centres
that are able to undertake early phase clinical trials. While a direct comparison against
other prognostic scores is not possible due to the clinical data available, in comparison
of model performance, the ROPRO score, calculated using information from more than
120,000 patients provided a high AUC value than the Wellness Score. As more samples
become available where outcome data is available on sufficient patients, we will analyse the
value of the protein signature using orthogonal methods more applicable to the selection
of patients who are sufficiently well and able to enrol in a clinical trial. When the Wellness
Score was enhanced with additional metrics it provided more confident results. PS alone
was not such a reliable means of assessing patients with regards to overall survival but
was useful in increasing the strength of the Wellness Score. While the three different scores
all were useful predictors of overall survival, the Wellness Score has an advantage over
the others in our aim to potentially produce a more objective scoring system in the future,
based upon the Wellness Score, in a clinical setting. PPM score includes the amount of
disease sites which is a complex and subjective metric that is not routinely collected by
clinical trials. PEPS includes PS which is based upon subjective assessment. Therefore, the
Wellness Score is the most appropriate to be followed in further, future studies.
A limitation of this study is the low number of patients. Larger scale testing of the
Wellness Score would be needed before translation into a clinical setting. The data collection
window for the validation set was shorter than the discovery set. Having the same data
collection period after the first patient had consented would have given more comparable
data. Another limitation is the lack of healthy normal controls which would be needed to
assess whether the Wellness Score is influenced by cancer. A limitation of study design
with respect to machine learning analysis is that there were two patients with PS score
2 in the discovery set and none in the validation set, and therefore introducing bias into
the models. While the proteomic based scoring systems in this study have been shown
to provide stronger correlates with patient overall survival than PS, they are also more
invasive and costly than PS to determine. Using antibody-based techniques with highly
specific antibodies to each of the three identified proteins may provide greater sensitivity
as prognostic biomarkers. Exploration of the relative contribution of each protein to a
composite score, and whether one protein alone would provide sufficient clinical utility
could also be explored in such a confirmatory study. A comparison should also be made to
established prognostic tools currently in use in this patient population such as the Royal
Marsden prognostic score (RMH Score) [45].
5. Conclusions
In this study we assessed the prognostic value of a derived proteomic signature and
found that such a signature had use as a means of determining the appropriate enrolment
of patients into early phase trials. We have shown that proteomics enhanced PS, and
other means that we have assessed, have a higher discriminatory capability than the
standard metric of PS by combining the existing assessments with SWATH-MS proteomic
data. The Wellness Score created in this study can potentially provide a more objective
prognostic scoring that one that can differ depending upon the assessor. While integrating
patient assessment and clinical observation can provide a stronger predictor of overall
survival, they cannot be translated into a routine clinic-based test. We can now verify
the value of this approach and assess the use of these proteins more generally as markers
for cancer. Specifically, we have identified three proteins, previously associated with
cancer which warrant further investigation as to their clinical utility (either alone or in
combination) to predict overall survival more accurately as a prelude to incorporating
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them into patients’ pre-trial screening procedures for their eligibility to enrol into an early
phase cancer clinical trial.
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